AMENDMENTS

Please enter the following amendments without prejudice or disclaimer.

In the claims:

Please cancel claims 3-10, 13-16, 18, 19, 21-26 and 29-32 without prejudice to renewal.

Please add the new claims as follows:

SUB B1 D1

--33. (New) A method of treating a disease responsive to a biologically active molecule in a mammal, comprising:

creating an immune-privileged site in a mammal by administering an effective amount of retinal pigmented epithelial (RPE) cells and co-administering to the site a second cell population that supplies an effective amount of the biologically active molecule, wherein said second cell population is allogeneic to the mammal.

34. (New) The method of claim 33 wherein said biologically active molecule is a neurotransmitter.

35. (New) The method of claim 33 wherein said biologically active molecule is a hormone.

36. (New) The method of claim 33 wherein said biologically active molecule is a cytokine inhibitor.

37. (New) The method of claim 33 wherein said biologically active molecule is selected from the group consisting of a polypeptide growth factor, cytokine, and polypeptide differentiation factor.

38. (New) The method of claim 37 wherein said biologically active molecule is selected from the group consisting of an interleukin, chemokine, interferon, colony stimulating factor and angiogenic factor.

39. (New) The method of claim 33 wherein said second cell population are cells transformed by a nucleic acid encoding said biologically active molecule.

40. (New) The method of claim 33 wherein said RPE cells are transformed by a nucleic acid encoding a biologically active molecule.

41. (New) The method of claim 33 wherein said RPE cells or cells of said second cell population are attached to a matrix prior to administration.

42. (New) The method of claim 33 wherein said RPE cells and cells of said second cell population are attached to a matrix prior to administration.

43. (New) The method of claim 33 wherein said administering and said co-administering is by transplantation.

44. (New) The method of claim 33 wherein said RPE cells are administered in a dose ranging from 10^3 to 10^7 cells.

45. (New) The method of claim 33 wherein said second cell population is co-administered in a dose ranging from 10^3 to 10^7 cells.

46. (New) The method of claim 33, further comprising re-administering RPE cells to the site in an effective amount to sustain the immune-privileged site.

47. (New) The method of claim 33, further comprising re-administering RPE cells or cells of said second cell population to the site in an effective amount to sustain a therapeutic effect.

SUB E4

48. (New) The method of claim 33 further comprising re-administering RPE cells and cells of said second cell population in amounts effective to sustain a therapeutic effect, wherein the RPE cells and the cells of the second population are attached to a matrix prior to re-administration.

D' CONT.

49. (New) The method according to claim 33 wherein the RPE cells and the second cell population are co-administered as a single composition.

50. (New) The method according to claim 33 wherein the RPE cells and the second cell population are co-administered as separate compositions.

51. (New) The method of claim 33 wherein the disease is selected from the group consisting of a neurological disease, cardiac disease, endocrine disease, hepatic disease, pulmonary disease, metabolic disease and immunological disease.

52. (New) The method according to claim 51 wherein the disease is a neurological disease.

53. (New) The method according to claim 51 wherein the disease is a metabolic ~~disease~~.

SUB E5

54. (New) A pharmaceutical composition comprising retinal pigmented epithelial (RPE) cells, a second cell population, and a pharmaceutically acceptable carrier,

wherein said second cell population is allogeneic to said RPE cells and wherein said second cell population produces a biologically active molecule that is absent or defective in a disease.

SUB F2

55. (New) The composition of claim 54 wherein said biologically active molecule is a neurotransmitter.

D' CONT.

56. (New) The composition of claim 54 wherein said biologically active molecule is a hormone.

57. (New) The composition of claim 54 wherein said biologically active molecule is a cytokine inhibitor.

58. (New) The composition of claim 54 wherein said biologically active molecule is selected from the group consisting of a polypeptide growth factor, cytokine, and polypeptide differentiation factor.

59. (New) The composition of claim 54 wherein said biologically active molecule is selected from the group consisting of an interleukin, chemokine, interferon, colony stimulating factor and angiogenic factor.

SUB E6

60. (New) A pharmaceutical composition comprising retinal pigmented epithelial (RPE) cells and a second cell population, wherein said second cell population is allogeneic to said RPE cells, wherein said second cell population produces a biologically active

molecule that is absent or defective in a disease and wherein said RPE cells and the cells of the second cell population are attached to a matrix.

SUB E6

61. (New) A compartmentalized kit adapted to receive a first container adapted to contain retinal pigmented epithelial (RPE) cells and a second container adapted to contain a second cell population, wherein said RPE cells are allogeneic to said second cell population and wherein said second cell population produces a biologically active molecule that is absent or defective in a disease.

D' CONT' SUB F3

62. (New) A compartmentalized kit according to claim 60, wherein the second cell population comprises insulin-producing cells.

63. (New) A compartmentalized kit according to claim 62, wherein the insulin-producing cells are pancreatic islet of Langerhans cells.

SUB E7

64. (New) An article of manufacture, comprising:

a packaging material;

retinal pigmented epithelial (RPE) cells contained within said packaging material, wherein said RPE cells are effective for creating an immune-privileged site in a mammal;

a second cell population contained within said packaging material, wherein said second cell population produces a biologically active molecule and wherein said second cell population is allogeneic to said RPE cells; and

wherein said packaging material contains a label that indicates that said RPE cells can be used for creating an immune-privileged site in a mammal.--